ST-2; a Non-invasive Fibrosis Marker for Chronic Hepatitis B

Sequela of Chronic Liver Disease Clinical Trial

Official title:

The Ability of Prediction of Fibrosis for ST-2 as a Non-invasive Marker in Chronic Hepatitis B

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01633554
• Other study ID #: 24190708
• Secondary ID: IKalkan24190708
• Status: Recruiting
• Phase: N/A
• First received: July 1, 2012
• Last updated: July 3, 2012
• Start date: January 2011
• Est. completion date: September 2012

Study information

• Verified date: July 2012
• Source: Turkiye Yuksek Ihtisas Education and Research Hospital
• Contact: Ismail H KALKAN, MD
• Phone: +90 312 437 67 78
• Email: drismailster[@]gmail.com
• Is FDA regulated: No
• Health authority: 'Turkey:Turkish Gastroenterology Organization'
• Study type: Observational

Clinical Trial Summary

IL-33 is a recently identified number of the IL-1 family. Hepatic over-expression of IL-33 has been recently linked to liver fibrosis. ST-2 exerts pro-inflammatory effects of IL-33. We aimed to determine ability of ST2 to predict fibrosis in chronic hepatitis B.

Description:

ST-2 is an IL-1 receptor family member and exists in both a membrane-bound isoform and a soluble (sST2) isoform. It has a functional ligand (Interleukin-33) and via ST-2/IL-33 inflammation and immunity is regulated. Hepatic over-expression of IL-33 has been recently linked to liver fibrosis. ST-2 exerts pro-inflammatory effects of IL-33. We aimed to determine ability of ST2 to predict fibrosis in chronic hepatitis B.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 95
• Est. completion date: September 2012
• Est. primary completion date: July 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Clinical diagnosis of chronic hepatitis B or liver cirrhosis

Exclusion Criteria:

• Accompanying chronic inflammatory disease

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Hepatitis B
• Hepatitis B, Chronic
• Hepatitis, Chronic
• Liver Diseases
• Sequela of Chronic Liver Disease

Locations

Country	Name	City	State
Turkey	Türkiye Yüksek Ihtisas Education and research Hospital	Altindag	Ankara

Sponsors (1)

Lead Sponsor	Collaborator
Turkiye Yuksek Ihtisas Education and Research Hospital

Country where clinical trial is conducted

Turkey,